Werewolf Therapeutics to Present at the Evercore ISI HealthCONx Conference
WATERTOWN, Mass., Nov. 22, 2023 (GLOBE NEWSWIRE) — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq:HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf, and Randi Isaacs, M.D., Chief Medical Officer of Werewolf, will participate in a fireside chat at 8:20 AM ET on November 29 at the Evercore ISI HealthCONx Conference, taking place November 28-30, 2023, in Miami, Florida.
Related news for (HOWL)
- Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer
- 24/7 Market News Snapshot 08 October, 2025 – Werewolf Therapeutics, Inc. Common Stock (NASDAQ:HOWL)
- Don’t Miss Out: MoBot’s Latest Stock Updates 09/22/25 05:00 PM
- MoBot alert highlights: NASDAQ: LIMN, NASDAQ: SLE, NYSE: BFLY, NASDAQ: SLNH, NASDAQ: HOWL (09/22/25 04:00 PM)
- MoBot alert highlights: NASDAQ: KITT, NASDAQ: VUZI, NASDAQ: HOWL, NASDAQ: BETRW, NASDAQ: KOD (09/22/25 01:00 PM)